Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Cyclopharm Limited ( (AU:CYC) ).
Cyclopharm Limited has announced a revised date for its Annual General Meeting, now scheduled for May 30, 2025, with the election of directors as a key agenda item. The new deadline for director nominations is set for April 9, 2025. This announcement, approved by CEO James McBrayer, is significant for stakeholders as it outlines the company’s governance timeline and potential leadership changes.
More about Cyclopharm Limited
Cyclopharm Limited is an ASX-listed radiopharmaceutical company that serves the global medical community. The company focuses on improving patient care outcomes through its core product, Technegas®, which is used for functional lung ventilation imaging. Technegas® is a radioactive carbon dispersion inhaled by patients for imaging purposes, historically used for diagnosing pulmonary embolism and now also applied in conditions like COPD, asthma, and pulmonary hypertension.
YTD Price Performance: -29.43%
Average Trading Volume: 170,435
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$131.1M
Learn more about CYC stock on TipRanks’ Stock Analysis page.